158 related articles for article (PubMed ID: 15300792)
21. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
22. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
23. Ionizing radiations in Caenorhabditis elegans induce poly(ADP-ribosyl)ation, a conserved DNA-damage response essential for survival.
Dequen F; Gagnon SN; Desnoyers S
DNA Repair (Amst); 2005 Jul; 4(7):814-25. PubMed ID: 15923155
[TBL] [Abstract][Full Text] [Related]
24. Poly ADP-ribose polymerase-1 and health.
Kirkland JB
Exp Biol Med (Maywood); 2010 May; 235(5):561-8. PubMed ID: 20463295
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Virág L
Pharmacol Res; 2005 Jul; 52(1):83-92. PubMed ID: 15911336
[TBL] [Abstract][Full Text] [Related]
26. NAD(+) consumption in carcinogen-treated hamster cells overexpressing a dominant negative mutant of poly(ADP-ribose) polymerase.
Küpper JH; Müller M; Wolf I
Biochem Biophys Res Commun; 1999 Nov; 265(2):525-9. PubMed ID: 10558902
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose)polymerase inhibition - where now?
Woon EC; Threadgill MD
Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
[TBL] [Abstract][Full Text] [Related]
28. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
29. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
[TBL] [Abstract][Full Text] [Related]
32. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
33. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-ribosyl)ation in carcinogenesis.
Masutani M; Fujimori H
Mol Aspects Med; 2013 Dec; 34(6):1202-16. PubMed ID: 23714734
[TBL] [Abstract][Full Text] [Related]
35. Chemopotentiation by PARP inhibitors in cancer therapy.
Tentori L; Graziani G
Pharmacol Res; 2005 Jul; 52(1):25-33. PubMed ID: 15911331
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitor development for systemic cancer targeting.
Zaremba T; Curtin NJ
Anticancer Agents Med Chem; 2007 Sep; 7(5):515-23. PubMed ID: 17896912
[TBL] [Abstract][Full Text] [Related]
38. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment.
Kumari SR; Mendoza-Alvarez H; Alvarez-Gonzalez R
Cancer Res; 1998 Nov; 58(22):5075-8. PubMed ID: 9823314
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Szabó C
Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
[TBL] [Abstract][Full Text] [Related]
40. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.
Griffin RJ; Curtin NJ; Newell DR; Golding BT; Durkacz BW; Calvert AH
Biochimie; 1995; 77(6):408-22. PubMed ID: 7578423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
